Indications and uses
Smooth on to cleansed face and throat.
Smooth on to cleansed face and throat.
Pump the nozzle 2 times onto the palm. Gently massage the gel onto the facial skin using an upward motion.
Glycerin 13.80%
Glycerin - Skin Protectant
Smooth on to cleansed face and throat.
Pump the nozzle 2 times onto the palm. Gently massage the gel onto the facial skin using an upward motion.
For external use only. Please do not use on damaged or broken skin.
If swallowed, get medical help or contact a Poison Control Center immediately.
If contact occurs, flush thoroughly with water.
Rash, irritation and/or abnormal reaction develop and last.
Store the product at room temperature. Avoid exposure to excessive heat and direct sunlight. Use within 3-6 months if opened. Can be stored up to 2 years if unopened.
Manufactured by Eaudeleman Cosmetic Co. Ltd.
Nishi Shinjuku 7-16-7, Shijuku-ku, Tokyo, Japan 160-0023
Distributed by JUC Group Inc.
411 E. Huntington Drive, Suite 205
Arcadia, CA 91006
Phone: (626)574-8588
WATER, BUTYLENE GLYCOL, SILK FIBROIN, DIGLYCERIN, HYALURONATE SODIUM, SUS CROFA PLACENTA, SOY PROTEIN, NEPIDERMIN, MARINE COLLAGEN SOLUBLE, MANNITOL, METHYLPARABEN
| Class | Version | Type | Effective |
|---|---|---|---|
| GLYCERIN Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| a62a50ac-1535-4461-9768-8ae703e2e9fb | Product name | 1 | 20210525 |
| 9514609b-a2a9-f8ec-6ba6-3f8e5ee89877 | Product name | 1 | 20140508 |
| bc07ef78-e82d-0c19-31f4-31f263780582 | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 69893-001-01 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d1-29a0-f424-e053-dadaa90a57ce | Eaudeleman Cosmetic Co.; Ltd |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 69893-001-01 | Silkriller 3D Gold Pure Rich Gel | 30 mL in 1 PACKAGE | GEL | 30 | 3165 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| GLYCERIN | ACTIVE INGREDIENT | PDC6A3C0OX | 3165 | |
| GLYCERIN | ACTIVE MOIETY | PDC6A3C0OX | 3165 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 3165 | |
| DIGLYCERIN | INACTIVE INGREDIENT | 3YC120743U | 3165 | |
| HYALURONATE SODIUM | INACTIVE INGREDIENT | YSE9PPT4TH | 3165 | |
| MANNITOL | INACTIVE INGREDIENT | 3OWL53L36A | 3165 | |
| MARINE COLLAGEN, SOLUBLE | INACTIVE INGREDIENT | 8JC99XGU4W | 3165 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 3165 | |
| NEPIDERMIN | INACTIVE INGREDIENT | TZK30RF92W | 3165 | |
| SILK FIBROIN | INACTIVE INGREDIENT | M09888Y92S | 3165 | |
| SOY PROTEIN | INACTIVE INGREDIENT | R44IWB3RN5 | 3165 | |
| SUS SCROFA PLACENTA | INACTIVE INGREDIENT | C8CV8867O8 | 3165 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 3165 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 69893-001 | 69893-001-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| GLYCERIN | PDC6A3C0OX | ACTIB |
| WATER | 059QF0KO0R | IACT |
| BUTYLENE GLYCOL | 3XUS85K0RA | IACT |
| SILK FIBROIN | M09888Y92S | IACT |
| DIGLYCERIN | 3YC120743U | IACT |
| HYALURONATE SODIUM | YSE9PPT4TH | IACT |
| SUS SCROFA PLACENTA | C8CV8867O8 | IACT |
| SOY PROTEIN | R44IWB3RN5 | IACT |
| NEPIDERMIN | TZK30RF92W | IACT |
| MARINE COLLAGEN, SOLUBLE | 8JC99XGU4W | IACT |
| MANNITOL | 3OWL53L36A | IACT |
| METHYLPARABEN | A2I8C7HI9T | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | 658 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | AEROSOL, FOAM / VAGINAL | 0.1 %w/w | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRA-ARTICULAR | 23 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | FILM / BUCCAL | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRADERMAL | 1 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION / INTRAVENOUS | 15200 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 3.6 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ENEMA / RECTAL | 0.18 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / INTRAVENOUS | 45 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / RECTAL | 1808 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / NASAL | 250 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | GRANULE, FOR SUSPENSION / ORAL | 6000 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | CAPSULE / ORAL | 1562 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION / INTRAVENOUS | 15400 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SHAMPOO, SUSPENSION / TOPICAL | 0.15 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SPRAY / TOPICAL | 0.2 %w/w | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC | 4.35 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM / TOPICAL | 3000 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | POWDER, FOR SUSPENSION / ORAL | 7093 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET / BUCCAL | 360 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ELIXIR / ORAL | 800 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / NASAL | 250 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION / SUBCUTANEOUS | 675 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | LOTION / TOPICAL | 351 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION / INTRAVENOUS | 2.5 %w/v | ||
| BUTYLENE GLYCOL | BUTYLENE GLYCOL | 3XUS85K0RA | SYSTEM / TOPICAL | 1400 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION, CONCENTRATE / ORAL | 1 mg/1ml | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRAMUSCULAR | 95 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, FILM COATED / ORAL | 2309 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / NASAL | 26 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SUSPENSION / SUBCUTANEOUS | 0.16 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | POWDER / RESPIRATORY (INHALATION) | 6 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SUSPENSION / SUBCUTANEOUS | 0.16 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | POWDER, FOR SOLUTION / ORAL | 3767 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / RECTAL | 0.13 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION / OPHTHALMIC | 4.7 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, ORALLY DISINTEGRATING / ORAL | 4364 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAVITREAL | 23 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SUSPENSION / OPHTHALMIC | 9 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRA-ARTICULAR | 0.24 %w/v | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / SUBCUTANEOUS | 99 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, COATED / ORAL | 177.7 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | GUM, CHEWING / BUCCAL | 891 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION / INTRAMUSCULAR | 106.6 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | POWDER, FOR SUSPENSION / INTRAMUSCULAR | 6.75 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | GEL / TOPICAL | 24 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / SUBCUTANEOUS | 22 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / EPIDURAL | 1 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | TABLET, EXTENDED RELEASE / ORAL | 0.17 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | OINTMENT / TOPICAL | 29 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 980.4 mg | ||
| HYALURONATE SODIUM | HYALURONATE SODIUM | YSE9PPT4TH | INJECTION, SUSPENSION / INTRAMUSCULAR | 23 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 543 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / PERINEURAL | 80 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / TOPICAL | 420 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | SOLUTION / ORAL | 869 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM / VAGINAL | 22 mg | ||
| MANNITOL | MANNITOL | 3OWL53L36A | INJECTION, SUSPENSION / INTRAMUSCULAR | 71 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 55a021d7-4937-4b18-8697-88d48379167e | 3b0775e4-c529-4048-ad74-537d439fd419 | 2015-11-04 | Warnings | 55a021d7-4937-4b18-8697-88d48379167e 3b0775e4-c529-4048-ad74-537d439fd419 |
Adverse event summaries are temporarily unavailable. Other product information remains available.